Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Check-CapSTU:7CC -2.54%36 5-Year Yield-on-Cost % is 0.00 as of Jul. 27, 2026. GuruFocus rates STU:7CC with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 64 Medical Diagnostics & Research companies, Check-Cap ranks worse than 1562498.44% on this metric.
Check-Cap's yield on cost for the quarter that ended in Dec. 2025 was 0.00.
The historical rank and industry rank for Check-Cap's 5-Year Yield-on-Cost % or its related term are showing as below:
STU:7CC's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.475 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Check-Cap 5-Year Yield-on-Cost % Related Terms
STU:7CC vs XWEL, NDRA, BIAF: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Check-Cap's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Check-Cap 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Check-Cap's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Check-Cap's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Check-Cap is calculated as
Check-Cap (STU:7CC) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 27, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Check-Cap and its competitors. According to the industry distribution chart, Check-Cap ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry.
Is Check-Cap's 5-Year Yield-on-Cost % too high?
Check-Cap's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Check-Cap ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Check-Cap has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Check-Cap's 5-Year Yield-on-Cost % compare to XWEL and NDRA?
According to the Medical Diagnostics & Research industry distribution chart, Check-Cap ranks #999999 out of 64 companies for 5-Year Yield-on-Cost %. This places Check-Cap in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.48, based on 64 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Check-Cap and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Check-Cap's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Check-Cap stock overvalued right now?
Check-Cap (STU:7CC) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Check-Cap's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Check-Cap (STU:7CC), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.
36GF Score
Get the complete analysis for STU:7CC
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7CC has been successfully added to your 
